Kara W Chew - Concepedia

Author

Kara W Chew

University of California, Los Angeles ORCID

Also Known As

ACTIV-2/A5401 Study Team, Accelerating COVID-19 Therapeutic Interventions and Vaccines–2/A5401 (ACTIV-2/A5401) Study Team, Augenbraun, Michael H, Chew, Kara W, Evering, Teresa H, Giganti, Mark J, Gordon, Kelley C., Hughes, Michael D, Hughes, Michael D., Hullsiek, Katherine Huppler

141

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

University of California, Los Angeles Harvard University University of North Carolina at Chapel Hill University of California San Diego Brigham and Women's Hospital

About

Kara W Chew is an author at University of California, Los Angeles specializing in medicine, public health, and epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	364
2	Public Health	7	7	169
3	Epidemiology	6	6	158
4	Health Sciences	1	1	11
5	Allergy	1	1	12

Kara W Chew

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Hepatitis E Virus–Associated Meningoencephalitis in a Lung Transplant Recipient Diagnosed by Clinical Metagenomic Sequencing Jamie A. Murkey, Kara W Chew, Margrit Carlson, Open Forum Infectious Diseases Lung TransplantationDiagnostic VirologyClinical Metagenomic SequencingTransplantationHepatitis E Virus	2017	76
Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection Rinki Deo, Manish C. Choudhary, Carlee Moser, Annals of Internal Medicine	2023	62
Prevalence and trends of polypharmacy among HIV-positive and -negative men in the Multicenter AIDS Cohort Study from 2004 to 2016 Deanna Ware, Frank J. Palella, Kara W Chew, PLoS ONE PharmacotherapyPolypharmacy PrevalencePreventive MedicineClinical EpidemiologyPublic Health	2018	59
Evolocumab in HIV-Infected Patients With Dyslipidemia Franck Boccara, Princy Kumar, Bruno Caramelli, Journal of the American College of Cardiology	2020	56
Demographics and natural history of HIV-1-infected spontaneous controllers of viremia Otto O. Yang, William G. Cumberland, Robert Daniel Ortiz Escobar, AIDS	2017	54
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial Manish C. Choudhary, Kara W Chew, Rinki Deo, Nature Microbiology Bamlanivimab TherapyPhase IiImmunologySars-cov-2 Escape MutationsMedicine	2022	51
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19 Kara W Chew, Carlee Moser, Eric S. Daar, Nature Communications	2022	46
Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection Anna Lidofsky, Jacinta A. Holmes, Eoin R. Feeney, The Journal of Infectious Diseases	2018	42
Treatment Outcomes With Pegylated Interferon and Ribavirin for Male Prisoners With Chronic Hepatitis C Kara W Chew, Scott Allen, Lynn E. Taylor, Journal of Clinical Gastroenterology	2009	41
Implementation of a Large System-Wide Hepatitis C Virus Screening and Linkage to Care Program for Baby Boomers Mariana Castrejón, Kara W Chew, Marjan Javanbakht, Open Forum Infectious Diseases	2017	41

Page 1